Streetbeat News

ALT

Altimmune, Inc.

Industry

Biotechnology

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Open

8.27

Mkt cap

541M

Volume

5.3M

High

8.54

P/E Ratio

-4.67

52-wk high

14.84

Low

7.46

Div yield

N/A

52-wk low

2.38

Altimmune presented new data at The Liver Meeting® 2024 showing that weekly subcutaneous doses of pemvidutide significantly reduce inflammatory lipids in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Portfolio Pulse from

November 15, 2024 | 4:15 pm

Altimmune's drug Pemvidutide is undergoing a phase 2b study for MASH treatment, with results expected in Q2 2025. The MASH market is projected to reach $7.64 billion by 2031. A successful FDA meeting for Pemvidutide in obesity treatment will lead to four phase 3 trials next year.

Portfolio Pulse from

November 13, 2024 | 9:00 pm

Altimmune's Pemvidutide shows promise in treating obesity and liver health, with significant weight loss results in Phase 2 trials. The company is financially positioned to support operations into 2026, aligning with future trial milestones.

Portfolio Pulse from

November 13, 2024 | 6:00 pm

ALT5 Sigma Corporation reported a record Q3 2024 with $4.94 million in revenue, driven by strong customer onboarding and upcoming launches of new capabilities for Alt5 Prime and Alt5 Pay.

Portfolio Pulse from

November 12, 2024 | 10:45 pm

Altimmune, Inc. held its Q3 2024 earnings call, discussing financial results and company updates. Key participants included CEO Vipin Garg and other executives. Analysts from Piper Sandler, Evercore, and B. Riley Securities participated.

Portfolio Pulse from

November 12, 2024 | 3:15 pm

Altimmune, Inc. has appointed Greg Weaver as its new Chief Financial Officer. Weaver will oversee finance, accounting, SEC reporting, and investor relations.

Portfolio Pulse from

November 11, 2024 | 12:45 pm

Altimmune, Inc. has granted equity awards to its new CFO, Gregory Weaver, as part of its 2018 Inducement Grant Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

November 11, 2024 | 12:45 pm

Altimmune is aiming to capture a significant share of the GLP-1 market, currently dominated by Eli Lilly and Novo Nordisk, by developing treatments that address the deficiencies of existing drugs.

Portfolio Pulse from

November 08, 2024 | 1:00 pm

Altimmune, Inc. has successfully completed its End-of-Phase 2 Meeting with the FDA for its obesity treatment candidate, pemvidutide. The company and the FDA have agreed on the design of the Phase 3 program, which will focus on the efficacy and safety of pemvidutide, leveraging its unique GLP-1/glucagon dual agonism.

Portfolio Pulse from

November 07, 2024 | 12:45 pm

ALT5 Sigma Corporation has appointed Ron Pitters, a FinTech executive, to its Board of Directors. This move is expected to enhance the company's strategic direction in blockchain-powered technologies.

Portfolio Pulse from

November 06, 2024 | 1:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.